The therapeutic application of Felodipin Teva focuses on providing consistent, long-term support within two primary cardiovascular domains.

Management of Chronic High Blood Pressure

This medication is generally relevant for the chronic, sustained management of Essential Hypertension, a condition defined by persistently high arterial pressure. The primary therapeutic domain is used for managing symptoms related to systemic imbalance, and the use may assist with continuous blood pressure reduction, which supports the easing of noticeable physiological strain on the cardiovascular system. This steady control contributes to reducing overall cardiovascular risk.

---

Support for Stable Effort-Induced Chest Discomfort

Felodipin Teva is also applied in addressing Chronic Stable Angina Pectoris, a condition where predictable chest pain or discomfort arises during physical activity. The therapeutic goal here is relevant for easing symptoms that interfere with daily comfort. This supportive relief may assist with easing the symptoms associated with acute or episodic changes, supporting patients during episodes of heightened discomfort.

---

Quick Fact: Relief for Persistent Systemic Strain

Felodipine is widely used in settings that require long-term assistance in symptom stabilization, particularly where persistent, high arterial pressure creates noticeable physiological strain. The overall supports the patient during difficult episodes by easing distress, which may assist with maintaining functional stability.

Felodipin Teva is approved for use in adults for the management of Hypertension and Stable Angina Pectoris. Regulatory documentation establishes specific population-based eligibility rules and absolute prohibitions.

Contraindicated Populations

Use is contraindicated for patients with pregnancy or known hypersensitivity to the drug or its components. Absolute cardiac exclusions include acute myocardial infarction, unstable angina pectoris, and decompensated heart failure. The medicine must also be avoided in patients with haemodynamically significant valvular or dynamic cardiac outflow obstruction.

Age-Related and Conditional Restrictions

Population Group	Eligibility Status	Regulatory Basis
Pediatric Population	Safety and efficacy not established	Not approved for use under 18 years.
Impaired Hepatic Function	Restricted use	Caution required due to expected elevated drug concentrations.
Elderly Patients	Conditional use	Requires consideration due to increased plasma concentrations with age.
Impaired Renal Function	Allowed	Typically permitted under standard conditions.
Lactation	Not recommended	Insufficient data on potential effect on the infant.

Felodipine's metabolism is primarily dependent on the Cytochrome P450 (CYP) 3A4 enzyme system in the liver. This metabolic pathway is the basis for several clinically important drug-drug interactions.

Interacting Medicines and Products

Interaction Type	Examples of Interacting Medicines/Categories	Effect on Felodipine Exposure	Clinical Relevance
Inhibitors of CYP3A4	Itraconazole, Ketoconazole (antifungals); Erythromycin (antibiotic); Cimetidine; Grapefruit juice	Increase (plasma concentration)	Risk of excessive blood pressure lowering (hypotension) and increased heart rate. Avoid use with strong inhibitors.
Inducers of CYP3A4	Phenytoin, Carbamazepine (anticonvulsants); Rifampicin (antibiotic); St. John's wort (herbal remedy)	Decrease (plasma concentration)	Risk of reduced effectiveness in lowering blood pressure. Avoid use with strong inducers.
Other Antihypertensives	Beta-blockers, ACE inhibitors, Diuretics	Additive effect	May cause an enhanced blood pressure lowering effect.
Specific Agents	Tacrolimus (immunosuppressant)	Increase (Tacrolimus blood concentration)	Tacrolimus levels must be closely monitored and its dose may require adjustment.

Patients should avoid grapefruit and grapefruit juice entirely while taking felodipine, as this can significantly increase the medicine's concentration. Caution should be exercised when co-administering any agent that affects the CYP3A4 enzyme, and close monitoring of blood pressure is essential. Elderly patients or those with impaired liver function may also experience elevated felodipine plasma concentrations.

How Felodipin Teva Works

Felodipin Teva is a calcium channel inhibitor that functions by binding selectively to the L-type voltage-dependent calcium channels found predominantly in the muscle cells of the arteries. This interaction prevents the essential influx of extracellular calcium ions ( Ca^2+) into the vascular smooth muscle cell interior.

The blockade of calcium prevents the activation of the intracellular machinery required for muscle fiber contraction, initiating a cascade that results in the relaxation and widening (vasodilation) of the small arteries (arterioles). This local mechanistic effect leads to a physiological consequence: a reduction in systemic vascular resistance and decreased impedance to blood flow.

This modulation of peripheral resistance causes a direct decrease in systemic arterial pressure. Furthermore, the drug's vasodilatory action extends to the coronary arteries, which increases blood flow to the myocardium and contributes to the resulting physiological adjustments within the circulatory system.

How to Use Felodipin Teva

The administration of Felodipin Teva, a prolonged-release tablet, is designed to ensure the active ingredient, felodipine, is released consistently over the dosing interval. The medicine is intended for oral administration and is typically used as part of a long-term plan for managing chronic conditions.

---

Official Administration Protocol

The fundamental usage pattern involves a once-daily schedule, preferably with the dose taken in the morning. To maintain the specialized release characteristics, the tablet must be swallowed whole with water and must not be crushed, chewed, or divided. Intake may occur on an empty stomach or with a light meal low in fat and carbohydrates. Furthermore, the concomitant consumption of grapefruit juice must be avoided as it affects how the medicine is used by the body.

---

Labeled Dosing and Schedule

Component	Guideline
Starting Dose	5 mg once daily; 2.5 mg once daily for specific populations
Maximum Dose	10 mg once daily
Titration Interval	Dose adjustments should not occur in intervals of less than two weeks

---

Population-Specific Use

An initial dose of 2.5 mg daily is generally considered for older adults and patients with impaired hepatic function. For individuals with renal impairment, no mandatory dose adjustment is typically required. Usage in the pediatric population is generally not recommended due to limited safety and efficacy data.

Research evidence / Overview of studies for Felodipin Teva

Evidence for use in Essential Hypertension (Chronic High Blood Pressure)

Research exploring the use of felodipine in managing essential hypertension has primarily involved Randomized Controlled Trials (RCTs). These studies included adults with high blood pressure, with specific RCTs focused on Older Adults with Isolated Systolic Hypertension [studies monitored]. Outcomes measured included the change in Systolic and Diastolic Blood Pressure (BP), as well as the effects on the presence of Left Ventricular Hypertrophy (LVH), a thickening of the heart walls [research examined].

Trials consistently monitored the difference in measurements of systolic and diastolic BP in the observed population compared to placebo. Comparative studies exploring felodipine alongside other common drug classes reported patterns related to measured blood pressure changes between the groups. Research focused on LVH monitored outcomes related to heart wall thickening and described patterns of change measured during the study period.

Evidence for use in Chronic Stable Angina Pectoris (Stable Effort-Induced Chest Discomfort)

The evidence base for felodipine in chronic stable angina involves studies relevant in trials assessing short-term or episodic symptom patterns, such as those related to physical discomfort during activity. Research designs included short-term, double-blind, placebo-controlled, crossover RCTs in adults with stable angina [research examined]. The studies explored outcomes related to physical discomfort by measuring Exercise Capacity/Duration on stress testing. Findings describe patterns observed in the studies where measurements of total exercise duration were compared between the felodipine group and placebo.

Long-term Studies and Major Follow-up

To understand the long-term data, researchers explored extended-duration research, including large, multi-year outcome trials. These studies were designed to track long-term health outcomes. Long-term outcome studies monitored findings related to major cardiovascular events (e.g., stroke and myocardial infarction) and described patterns observed in the group receiving felodipine compared to the placebo group. The follow-up durations used often extended over multiple years [studies observing responses over defined time intervals].

Research Gaps and Areas of Uncertainty

The evidence landscape, while broadly available for the core uses, contains research gaps. One major limitation is that long-term effects are not fully established with data specific only to felodipine; many cardiovascular outcome findings are drawn from trials where results are generalized across the broader Dihydropyridine Calcium Channel Blocker class [there is limited information for long-term outcomes]. Furthermore, research on safety and efficacy in the pediatric population (children and adolescents) is not established [evidence is limited].

Key Studies & References

1. Felodipine - StatPearls (General Review of Efficacy and Pharmacology)

Common questions about Felodipin Teva (FAQ)

Q: Can I use this medication if I am pregnant or breastfeeding?

According to official product information, this medicine has not been studied in pregnant women. Based on animal research, there is a potential for harm to an unborn fetus. Regulatory guidelines indicate that its use during pregnancy should only occur if the potential benefit to the mother justifies the potential risk to the unborn fetus. It is also currently unknown if this drug passes into human milk. Due to this uncertainty, official information advises caution when the medication is administered to a nursing woman.

---

Q: Is it safe to use this medication for long periods of time?

Official information mentions rare cases of liver damage have been reported with this medication. Liver function tests may be required for monitoring during extended treatment. When discontinuing the medication, the official label recommends that the dose be slowly reduced, as abrupt cessation may lead to withdrawal effects, such as rebound hypertension or rapid heart rate.

---

Q: Can children use this medication?

Official regulatory documents state that the safety and effectiveness of this medication have not been established for use in pediatric patients (children). Therefore, the medication is generally not indicated for use in children.

Felodipine Teva storage and disposal are governed by official regulatory requirements to ensure product stability and environmental safety.

Required Storage Conditions

This medication must not be stored above 25 °C and should not be frozen. The tablets must be protected from heat, moisture, and direct light and should be kept in a closed container. For safety, the product must be stored out of the sight and reach of children and should not be used past the expiry date.

Official Disposal Rules

Unused or expired Felodipine Teva must not be thrown away in household waste or disposed of via wastewater. Patients are instructed to consult a pharmacist for the proper method of disposal, ensuring compliance with local requirements for pharmaceutical waste.